Saturday, November 2, 2024
Canada’s Politics and Government News Source Since 1989
Saturday, November 2, 2024 | Latest Paper

John Bell and Stéphanie Michaud

Our country is at the tipping point of paving a pathway for patients to access new treatment approaches in a timely manner and can support the development of novel immunotherapies needed to treat Canadian cancer patients during this fragile post-pandemic recovery, write John Bell and Stéphanie Michaud. Photograph courtesy of Unsplash
Our country is at the tipping point of paving a pathway for patients to access new treatment approaches in a timely manner and can support the development of novel immunotherapies needed to treat Canadian cancer patients during this fragile post-pandemic recovery, write John Bell and Stéphanie Michaud. Photograph courtesy of Unsplash
Our country is at the tipping point of paving a pathway for patients to access new treatment approaches in a timely manner and can support the development of novel immunotherapies needed to treat Canadian cancer patients during this fragile post-pandemic recovery, write John Bell and Stéphanie Michaud. Photograph courtesy of Unsplash
Our country is at the tipping point of paving a pathway for patients to access new treatment approaches in a timely manner and can support the development of novel immunotherapies needed to treat Canadian cancer patients during this fragile post-pandemic recovery, write John Bell and Stéphanie Michaud. Photograph courtesy of Unsplash